Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Danforth, D. N.
Right arrow Articles by Cowan, K. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Danforth, D. N., Jr
Right arrow Articles by Cowan, K. H.

Annals of Surgical Oncology, Vol 5, Issue 2 150-158, Copyright © 1998 by Society of Surgical Oncology


ARTICLES

Selection of local therapy after neoadjuvant chemotherapy in patients with stage IIIA,B breast cancer

D. N. Danforth Jr, J. Zujewski, J. O'Shaughnessy, D. Riseberg, S. M. Steinberg, N. McAtee, M. Noone, C. Chow, U. Chaudhry, M. Lippman, J. Jacobson, P. Okunieff and K. H. Cowan
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

BACKGROUND: Stage IIIA,B breast cancer is commonly treated with neoadjuvant chemotherapy because of high objective response rates and improved operability. Criteria for subsequent selection of local therapy--mastectomy, radiotherapy, or both--are not well defined. We adopted a policy of selective local therapy based on rebiopsy of the breast and clinical axillary lymph node status at the time of best response to chemotherapy. METHODS: Between 1980 and 1993, 126 patients with stage IIIA,B breast cancer were treated with neoadjuvant chemotherapy and definitive local therapy. The long-term incidence of locoregional failure (in-breast, chest wall, axilla, supraclavicular, neck), relapse-free survival, and overall survival was determined. RESULTS: The overall clinical objective response rate to chemotherapy was 95.2%. Eighty-three patients underwent mastectomy, with negative margins achieved in 91.6%. Forty-two patients had breast preservation; the overall in-breast recurrence rate was 19.0% (8 of 42 patients). The overall locoregional recurrence rate by site was: chest wall-8.7% (11 of 126 patients), axilla-8.7% (11 of 126 patients), supraclavicular-5.6% (7 of 126 patients), and neck-4.0% (5 of 126 patients). The axillary recurrence rate was 6.6% (5 of 76 patients) for clinically negative axilla treated with radiotherapy only, and 12.0% (6 of 50 patients) for clinically positive axilla treated with surgery only. The overall long-term survival probabilities (6 years) according to stage were: stage IIIA-58.0%, stage IIIB(noninflam)-58.0%, stage IIIB(inflam)-36.0%. CONCLUSIONS: These findings support a selective approach to local therapy in patients with stage IIIA,B breast cancer. This approach provides local control in most patients, and allows for breast preservation and elimination of axillary dissection in selected patients.


This article has been cited by other articles:


Home page
Ann. Surg. Oncol.Home page
P. F. Escobar, R. J. Patrick, L. A. Rybicki, D. Hicks, D. E. Weng, and J. P. Crowe
Prognostic Significance of Residual Breast Disease and Axillary Node Involvement for Patients Who Had Primary Induction Chemotherapy for Advanced Breast Cancer
Ann. Surg. Oncol., June 1, 2006; 13(6): 783 - 787.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. A. Low, A. W. Berman, S. M. Steinberg, D. N. Danforth, M. E. Lippman, and S. M. Swain
Long-Term Follow-Up for Locally Advanced and Inflammatory Breast Cancer Patients Treated With Multimodality Therapy
J. Clin. Oncol., October 15, 2004; 22(20): 4067 - 4074.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
E. P. Mamounas
Tailoring Loco-Regional Therapy with Neoadjuvant Chemotherapy: Another Step in the Right Direction
Ann. Surg. Oncol., October 1, 2004; 11(10): 888 - 891.
[Full Text] [PDF]


Home page
JCOHome page
A. M. Chen, F. Meric-Bernstam, K. K. Hunt, H. D. Thames, M. J. Oswald, E. D. Outlaw, E. A. Strom, M. D. McNeese, H. M. Kuerer, M. I. Ross, et al.
Breast Conservation After Neoadjuvant Chemotherapy: The M.D. Anderson Cancer Center Experience
J. Clin. Oncol., June 15, 2004; 22(12): 2303 - 2312.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
D. N. Danforth Jr, K. Cowan, R. Altemus, M. Merino, C. Chow, A. Berman, U. Chaudhry, C. Shriver, S. M. Steinberg, and J. Zujewski
Preoperative FLAC/Granulocyte-Colony-Stimulating Factor Chemotherapy for Stage II Breast Cancer: A Prospective Randomized Trial
Ann. Surg. Oncol., July 1, 2003; 10(6): 635 - 644.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
L. F. Baron, P. L. Baron, S. J. Ackerman, D. D. Durden, and T. L. Pope Jr.
Sonographically Guided Clip Placement Facilitates Localization of Breast Cancer After Neoadjuvant Chemotherapy
Am. J. Roentgenol., February 1, 2000; 174(2): 539 - 540.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the Society of Surgical Oncology.